From 1 February 2018, low-dose codeine (≤ 15 mga) will no longer be
available over the counter (OTC).
affected products include low-dose codeine in combination with paracetamol or
non-steroidal anti-inflammatory drugs (NSAIDs) for pain relief, and some
preparations for the management of cold and flu symptoms.
decision to up-schedule all codeine products was made by the Therapeutic Goods
Administration (TGA). An extensive risk–benefit analysis and consultation
concluded that OTC medicines containing codeine have little additional
analgesic benefit compared with similar medicines without codeine, but are associated
with higher health risks.
change represents an opportunity for GPs and pharmacists to help people who
have been using OTC codeine find alternative treatments that are effective and
have a more favourable safety profile for each individual.
more information download the TGA factsheet. Click here
factsheets in community languages visit the NPS Medicinewise website by
professional who require more information visit the TGA website. Click here